**Table S2**. Mann-Whitney test *P*-values relating to the differences in log2 tumor/control ratios at week 3 for cetuximab monotherapy/control and cisplatin plus cetuximab/cisplatin alone between tumors with low and high EGFR expression as determined by different EGFR immunohistochemistry score thresholds

|  |  |  |
| --- | --- | --- |
| EGFR IHC score threshold  (</≥) | Cetuximab monotherapy vs control  *P*-value | Cisplatin + cetuximab vs  cisplatin alone  *P*-value |
| 150 | 0.026 | 0.11 |
| 160 | 0.026 | 0.11 |
| 170 | 0.027 | 0.040 |
| 180 | 0.015 | 0.024 |
| 190 | 0.0042 | 0.037 |
| 200 | 0.0013 | 0.013 |
| 210 | 0.0013 | 0.013 |
| 220 | 0.019 | 0.12 |
| 230 | 0.026 | 0.18 |
| 240 | 0.032 | 0.070 |
| 250 | 0.020 | 0.10 |

IHC, immunohistochemistry.